Head‐to‐head comparison of two senolytic therapies in a mouse model of tauopathy

Abstract

Background: Tau protein accumulation induces cellular senescence in Alzheimer's disease (AD). Treating tau transgenic mice with the senolytic therapy, dasatinib plus quercetin (DQ), to clear senescent cells reduced brain pathology and improved structure and function. DQ has since been moved into clinical AD trials.